Allison Bratzel
Stock Analyst at Piper Sandler
(4.43)
# 363
Out of 5,182 analysts
62
Total ratings
61.22%
Success rate
18.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Downgrades: Neutral | $7 → $4 | $1.50 | +166.67% | 2 | May 8, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $26 → $30 | $9.82 | +205.65% | 3 | Apr 22, 2026 | |
| HUMA Humacyte | Maintains: Neutral | $3 → $1 | $1.06 | -5.66% | 3 | Mar 30, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $42 → $56 | $34.32 | +63.17% | 3 | Mar 20, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $51 → $58 | $48.39 | +19.86% | 5 | Mar 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $87 → $100 | $75.71 | +32.08% | 5 | Feb 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $42.60 | -10.80% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $54.06 | +55.38% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $98.56 | +11.61% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.16 | +244.83% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $14 | $4.07 | +243.98% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $2.08 | +92.31% | 1 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $782.17 | +18.90% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $122.74 | -8.75% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $26.12 | +340.28% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $26.04 | -11.67% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $28.56 | -22.97% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $7.27 | +175.10% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $5.24 | +281.68% | 1 | Oct 13, 2023 |
enGene Therapeutics
May 8, 2026
Downgrades: Neutral
Price Target: $7 → $4
Current: $1.50
Upside: +166.67%
MeiraGTx Holdings
Apr 22, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $9.82
Upside: +205.65%
Humacyte
Mar 30, 2026
Maintains: Neutral
Price Target: $3 → $1
Current: $1.06
Upside: -5.66%
Tyra Biosciences
Mar 20, 2026
Maintains: Overweight
Price Target: $42 → $56
Current: $34.32
Upside: +63.17%
Scholar Rock Holding
Mar 4, 2026
Maintains: Overweight
Price Target: $51 → $58
Current: $48.39
Upside: +19.86%
Ionis Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $87 → $100
Current: $75.71
Upside: +32.08%
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $42.60
Upside: -10.80%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $54.06
Upside: +55.38%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $98.56
Upside: +11.61%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.16
Upside: +244.83%
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $4.07
Upside: +243.98%
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.08
Upside: +92.31%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $782.17
Upside: +18.90%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $122.74
Upside: -8.75%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $26.12
Upside: +340.28%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $26.04
Upside: -11.67%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $28.56
Upside: -22.97%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $7.27
Upside: +175.10%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $5.24
Upside: +281.68%